毒结清口服液联合VAD方案治疗骨髓瘤骨病30例临床观察  

Effect of Dujieqing Liquor Combined with VAD Chemotherapy in Treatment of Myeloma Bone Disease

作　　者：程纬民[1] 曾清[1] 许敏 何艾[1] 陆海颂[1] 雷宇 李雪萍 CHENG Weimin;ZENG Qing;XU Min;HE Ai;LU Haisong;LEI Yu;LI Xueping(The First Hospital Attached to Guangxi University of TCM,Nanning 530023,China)

机构地区：[1]广西中医药大学第一附属医院血液科,广西南宁530023

出　　处：《中国民族民间医药》2019年第1期119-121,共3页Chinese Journal of Ethnomedicine and Ethnopharmacy

基　　金：广西区卫生厅课题(Z20170278)

摘　　要：目的:观察毒结清口服液联合VAD化疗方案治疗骨髓瘤骨病(MBD)的临床疗效。方法:选取60例MBD患者随机分成2组,对照组予单纯VAD方案化疗,治疗组在化疗的基础上加服中药毒结清口服液治疗。观察两组患者的骨痛症状评分、血清β2微球蛋白(β2-MG)水平变化情况及临床疗效。结果:两组4个疗程治疗后的骨痛评分与治疗前比较均明显下降(P <0. 05),中药治疗组患者治疗后的骨痛评分显著低于对照组患者(P <0. 05);对照组β2-MG水平较治疗前明显下降(P <0. 05),治疗后治疗组的β2-MG水平明显低于对照组(P <0. 05);对照组的临床总有效率为63. 33%,中药治疗组总有效率为76. 67%,两组差异有统计学意义(P <0. 05)。结论:毒结清口服液联合VAD化疗能明显改善MBD患者骨痛评分和降低血清β2-MG水平,临床疗效较好。Objective To observe the effects of Dujieqing Liquor in combination with VAD regimen Chemotherapy on patients in Myeloma bone disease (MBD).Methods Sixty Patients were randomized to two groups:control group (30 pts)were treated with VAD regimen chemotherapy only;in addition to VAD regimen Chemotherapy ,TCM group (30 pts)were also treated with Dujieqing Liquor.Results Scores of bone ache in group TCM and in group control were lower than pretherapy (P <0.05 ).β2 -MG lever in TCM group were lower than those in control group (P <0.05).Total clinical efficiencies in TCM group were higher than those in con- trol group (P <0.05 ).Conclusion Dujieqing Liquor combined with VAD Chemotherapy can degradeβ2 -MG lever,also can improve symptom of bone ache and the clinical efficiencies.

关 键 词：骨髓瘤骨病 中西医结合治疗 毒结清口服液 

分 类 号：R733.3[医药卫生—肿瘤]